el-Denshary E S, Ageel A M, el-Wakkad I, Abu-Jayyab A R
Life Sci. 1987 Apr 13;40(15):1531-5. doi: 10.1016/0024-3205(87)90386-9.
Results show that bromocriptine induced marked alterations in plasma levels of cholesterol and lipids in response to acute and chronic administrations in rats. Two hours after an I.P. dose of 10 mg/kg, bromocriptine mesylate caused significant reductions in plasma levels of total high density lipoprotein (HDL) and high density lipoprotein cholesterol (HDL cholesterol). At a dose of 20 mg/kg, bromocriptine mesylate induced significant elevations in plasma levels of total cholesterol, total HDL, HDL cholesterol, total low density lipoproteins (LDL), and low density lipoprotein cholesterol (LDL cholesterol). Injected at a dose of 4 or 10 mg/kg daily for 14 consecutive days, bromocriptine mesylate caused significant increases in plasma levels of total cholesterol, LDL cholesterol and total LDL whereas the levels of HDL cholesterol, total HDL triglycerides (TG) were reduced. At a dose of 20 mg/kg all parameters were significantly increased. Marked hyperglycaemia was noticed in response to doses of 10, 15 and 20 mg/kg injected daily for 14 consecutive days or 2 hrs after a single administration of 15 mg/kg. Plasma insulin activity was reduced 2 hours after injection of bromocriptine at a dose of 15 mg/kg Likewise, a significant reduction in plasma insulin activity was observed in response to daily I.P. injections of bromocriptine at a dose of 15 mg/kg. Hyperglycaemic and hypoinsulinaemic effects of bromocriptine (acute and chronic) were markedly decreased when sulpiride, a dopaminergic D2 antagonist, was injected at an I.P. dose of 10 mg/kg before bromocriptine. Plasma ACTH activity was significantly increased in response to bromocriptine (15 mg/kg I.P.) in acute and chronic experiments. This effect was markedly diminished when sulpiride was injected prior to bromocriptine. In conclusion, bromocriptine induced marked elevations in plasma levels of total cholesterol and lipids which are likely to be related to hyperglycaemic and hypoinsulinaemic effects.
结果显示，在大鼠急性和慢性给药后，溴隐亭可引起血浆胆固醇和脂质水平的显著变化。腹腔注射10mg/kg剂量的甲磺酸溴隐亭两小时后，血浆中总高密度脂蛋白（HDL）和高密度脂蛋白胆固醇（HDL胆固醇）水平显著降低。在20mg/kg剂量时，甲磺酸溴隐亭可使血浆总胆固醇、总HDL、HDL胆固醇、总低密度脂蛋白（LDL）和低密度脂蛋白胆固醇（LDL胆固醇）水平显著升高。连续14天每天以4或10mg/kg剂量注射，甲磺酸溴隐亭可使血浆总胆固醇、LDL胆固醇和总LDL水平显著升高，而HDL胆固醇、总HDL甘油三酯（TG）水平降低。在20mg/kg剂量时，所有参数均显著升高。连续14天每天注射10、15和20mg/kg剂量或单次注射15mg/kg后2小时，可观察到明显的高血糖。在15mg/kg剂量注射溴隐亭后两小时，血浆胰岛素活性降低。同样，每天腹腔注射15mg/kg剂量的溴隐亭也可使血浆胰岛素活性显著降低。在注射溴隐亭前腹腔注射10mg/kg剂量的多巴胺能D2拮抗剂舒必利后，溴隐亭（急性和慢性）的高血糖和低胰岛素作用显著减弱。在急性和慢性实验中，溴隐亭（15mg/kg腹腔注射）可使血浆促肾上腺皮质激素（ACTH）活性显著升高。在溴隐亭之前注射舒必利后，这种作用明显减弱。总之，溴隐亭可使血浆总胆固醇和脂质水平显著升高，这可能与高血糖和低胰岛素作用有关。
